Race Oncology Ltd., of Victoria, Australia, completed a placement of about 9.9 million shares priced at A32 cents (US25 cents) apiece for gross proceeds of about A$3.2 million. In addition to operational funding, proceeds will be used to fund manufacturing of Bisantrene for U.S. registrational trials and for expansion of the named patient program.